Titlebook: New Antimicrobials: For the Present and the Future; I.W. Fong Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive l

CRANK

Predigest

Temporal-Lobe

New Oxazolidinone: Tedizolids approved for clinical use in the United States in 2000 and tedizolid was approved in 2014. Although resistance is rare to linezolid among gram-positive bacteria, tedizolid has greater potency, less frequent dosing, reduced hematological side effects, and less concern for monoamine oxidase inhibiti

催眠藥

New Tetracyclines: Eravacycline and Omadacyclinereased resistance, even to the semisynthetic second-generation compounds, doxycycline and minocycline, introduced in the 1960s–1970s. In the early 2000s, modification of the structure of minocycline led to the development of the third-generation, broader-spectrum tigecycline. Although effective agai

blight

幾何學(xué)家

ineptitude

New Systemic Antifungal: Isavuconazolene marrow transplantations, and autoimmune diseases. The need for new antifungal agents has arisen with the emergence of azole-resistant . species and multiresistant ., besides the shortcomings of existent agents. The azole class of agents is associated with potentially dangerous drug-drug interacti

Creditee

的是兄弟

New Antiretroviral Agents for HIV Infectionerapeutics. Once a death sentence, now HIV can be controlled with a single pill daily that result in lifespan almost the same as normal people. The advent of this triumph started with the development of potent combination therapy delivered in a single tablet or capsule, the first triple combination

斷言